Oncocross
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Oncocross uses artificial intelligence to analyze biological and chemical data in order to identify new uses for existing drugs, a process known as drug repurposing, and to support the discovery of new medicines.
Its services are aimed at pharmaceutical companies, research institutions, and others working in drug development. The company is listed on KOSDAQ, South Korea's technology and small-cap stock exchange.
Summary is AI-generated and may contain errors · figures from DART filings
Oncocross in five facts
What does Oncocross do?
Oncocross uses artificial intelligence to analyze biological and chemical data in order to identify new uses for existing drugs, a process known as drug repurposing, and to support the discovery of new medicines.
Where is Oncocross listed and in which sector?
Oncocross (Korean name: 온코크로스) trades under KRX code 382150 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Oncocross?
Its market capitalisation was US$31.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Oncocross's latest annual revenue and operating profit?
For fiscal year 2025, Oncocross reported revenue of US$279.6K, an operating loss of US$6.7M and a net loss of US$6.7M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was down 65.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (abbreviated)Oct 8
- Conversion price adjustmentSep 28
- Material event report (decision to redeem own convertible bonds early)
OncocrosS Co., Ltd. has decided on September 18, 2026 to acquire US$1.81M (20% of the total issuance) of its own convertible bonds issued on July 25, 2025, for a total acquisition amount of US$1.86M through exercise of a call option, with the bonds to mature on July 25, 2030. The acquisition will be funded from the company's own funds and completed through over-the-counter purchase, leaving US$7.25M in outstanding bonds.
Capital raise · Sep 18 - Conversion price adjustmentSep 9
- Material management matter relevant to investment decisionsSep 1
- Completion report on merger, etc. (merger)M&A · Jul 1
- [Attachment amended] Material event report (merger)M&A · Apr 17
- [Attachment amended] Material event report (merger)M&A · Apr 16
- [Amended] Material event report (merger)M&A · Apr 16 · 2 versions
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Oncocross reported consolidated results for FY2025: revenue of US$261K (−64.4% year on year), an operating loss of US$6.13M and a net loss of US$6.16M.
Earnings · Feb 10 - Material event report (convertible bonds)Capital raise · Jan 30
- Decision to acquire shares/equity in another company (voluntary)M&A · Jan 7